prof. MUDr. Jiří Mayer, CSc.
Professor, Department of Internal Medicine - Hematology and Oncology
correspondence Address:
Jihlavská 340/20, 625 00 Brno
| phone: | +420 532 23 3643, 3603 |
|---|---|
| e‑mail: |
| social and academic networks: |
|---|
Total number of publications: 1749
2025
-
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy
Blood, year: 2025, volume: 146, edition: 5, DOI
-
Total psoriasis regression in a patient with chronic myeloid leukemia treated using nilotinib
Annals of Hematology, year: 2025, volume: 104, edition: 3, DOI
-
Treatment Cessation in Chronic Myeloid Leukemia: Evidence and Uncertainties
Hematological Oncology, year: 2025, volume: 43, edition: 6, DOI
2024
-
AKCELEROVANÁ FÁZE BY MĚLA BÝT SOUČÁSTÍ KLASIFIKACE CHRONICKÉ MYELOIDNÍ LEUKEMIE I V ÉŘE EXISTENCE INHIBITORŮ TYROZINKINÁZ
Year: 2024, type: Conference abstract
-
ANALYSIS OF ALTERNATIVE THERAPEUTIC OPTIONS FOR ACUTE MYELOID LEUKEMIA PATIENTS RESISTANT TO VENETOCLAX BASED ON DRUG SCREENING AND EXPRESSION PROFILING
Year: 2024, type: Conference abstract
-
ANALÝZA GENOMU NEMOCNÝCH S AKUTNÍ MYELOIDNÍ LEUKEMIÍ (AML) METODOU OPTICKÉHO MAPOVÁNÍ (OGM)
Year: 2024, type: Conference abstract
-
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study
JOURNAL OF HEMATOLOGY & ONCOLOGY, year: 2024, volume: 17, edition: 1, DOI
-
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
New England Journal of Medicine, year: 2024, volume: 391, edition: 10, DOI
-
ASOCIAČNÍ ANALÝZA ZÁRODEČNÉ VARIANTY JAK2:P.R1063H SE SOMATICKÝMI ŘÍDÍCÍMI ONKOGENY U KOHORTY 400 PACIENTŮ S AKUTNÍ MYELOIDNÍ LEUKEMIÍ Z ČESKÉ REPUBLIKY
Year: 2024, type: Conference abstract
-
Clinical efficacy and safety of first-line nilotinib or imatinib therapy in patients with chronic myeloid leukemia-Nationwide real life data
Cancer Medicine, year: 2024, volume: 13, edition: 17, DOI